MiMedx Group, Inc. provided sales guidance for the year 2022. The company maintained its outlook for 2022, as disclosed in its earnings release for the year ended December 31, 2021, including that it expects net sales of its continuing portfolio of Advanced Wound Care products, which were $240.0 million in 2021, to grow 11% to 14% in 2022.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.255 USD | +2.18% | -3.06% | -16.99% |
30/04 | Transcript : MiMedx Group, Inc., Q1 2024 Earnings Call, Apr 30, 2024 | |
30/04 | Earnings Flash (MDXG) MIMEDX GROUP Posts Q1 Revenue $84.7M, vs. Street Est of $79.4M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.99% | 104.8Cr | |
-24.53% | 12Cr | |
-13.93% | 6.3Cr | |
0.00% | 5.75Cr | |
-8.98% | 5.07Cr |
- Stock Market
- Equities
- MDXG Stock
- News MiMedx Group, Inc.
- MiMedx Group, Inc. Provides Sales Guidance for the Year 2022